Albert Bourla, AP Images
November 2, 2021 11:08 AM EDT
Pharma

Pfiz­er re­veals de­lays across the board for its clin­i­cal gene ther­a­py pro­grams

Nicole DeFeudis

Editor

At JP Mor­gan 2020, a year af­ter tak­ing the reins at Pfiz­er, Al­bert Bourla claimed the com­pa­ny was poised to be­come a leader in gene …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times